| 000 | 01616 a2200433 4500 | ||
|---|---|---|---|
| 005 | 20250511220401.0 | ||
| 264 | 0 | _c19910620 | |
| 008 | 199106s 0 0 eng d | ||
| 022 | _a0277-3732 | ||
| 024 | 7 |
_a10.1097/00000421-199106000-00001 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aAhmann, D L | |
| 245 | 0 | 0 |
_aA randomized trial of cyclophosphamide, doxorubicin, and prednisone versus cyclophosphamide, 5-fluorouracil, and prednisone in patients with metastatic breast cancer. _h[electronic resource] |
| 260 |
_bAmerican journal of clinical oncology _cJun 1991 |
||
| 300 |
_a179-83 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Randomized Controlled Trial | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xadverse effects |
| 650 | 0 | 4 |
_aBreast Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aCyclophosphamide _xadministration & dosage |
| 650 | 0 | 4 |
_aDoxorubicin _xadministration & dosage |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aFluorouracil _xadministration & dosage |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPrednisone _xadministration & dosage |
| 650 | 0 | 4 |
_aSoft Tissue Neoplasms _xsecondary |
| 650 | 0 | 4 | _aSurvival Rate |
| 700 | 1 | _aSchaid, D J | |
| 700 | 1 | _aIngle, J N | |
| 700 | 1 | _aBisel, H F | |
| 700 | 1 | _aSchutt, A J | |
| 700 | 1 | _aBuckner, J C | |
| 700 | 1 | _aLong, H J | |
| 700 | 1 | _aRubin, J | |
| 773 | 0 |
_tAmerican journal of clinical oncology _gvol. 14 _gno. 3 _gp. 179-83 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1097/00000421-199106000-00001 _zAvailable from publisher's website |
| 999 |
_c2037682 _d2037682 |
||